Daniel DeAngelo, MD, PhD
Dr. Daniel J. DeAngelo is associate professor of medicine at Harvard Medical School and a physician within the Adult Leukemia Program at Dana-Farber Cancer Institute in Boston, Massachusetts.
He earned his MD and PhD in molecular genetics from Albert Einstein College of Medicine of Yeshiva University in Bronx, New York. He completed his internship and residency at Massachusetts General Hospital in Boston and clinical fellowships in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, both in Boston.
Dr. DeAngelo’s research interests include novel immunotherapeutic approaches to the treatment of acute myelogenous leukemia and myelodysplasia. I am currently developing leukemia tumor vaccines from patients with AML or advanced myelodysplasia and will be assaying for immunological and serological responses.
Dr. DeAngelo’s clinical research focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes and myeloproliferative disorders. He serves on the leukemia core committee for the Cancer and Leukemia Group B (CALGB) and is principal and co-investigator of several ongoing clinical protocols. He has a particular interest in the treatment of young adults with leukemia, particularly acute lymphoblastic leukemia.
Dr. DeAngelo is actively involved in a number of professional societies such as the American Society of Hematology and the American Society of Clinical Oncology. In addition, he serves as a member of the NCCN CML and ALL guidelines committee. Dr DeAngelo has authored or coauthored more than 200 original peer-reviewed manuscripts, review articles, and book chapters and has presented his work nationally and internationally.